(54) Title: CELL PRODUCTION

(57) Abstract: A method of producing neurectoderm cells, which method includes providing a source of early primitive ectoderm-like (EPL) cells; a conditioned medium as hereinbefore defined; or an extract therefrom exhibiting neural inducing properties; and contacting the EPL cells with the conditioned medium, for a time sufficient to generate controlled differentiation to neurectoderm cells.

2

Pluripotent cells from this time are confined to the germline. Differentiation of primitive ectoderm cells in the distal and anterior regions of the embryo is directed along the ectodermal lineage forming definitive ectoderm, a transient embryonic cell type fated to form neurectoderm and surface ectoderm.

5   Neurectoderm cells are found in the mammalian embryo in the neural plate, which folds and closes to form the neural tube. These cells are the precursors to all neural lineages. They have the capacity to differentiate into all neural cell types present in the central nervous system (CNS) and peripheral nervous system (PNS). In the CNS these cells include multiple neuron subtypes and glia (eg; 10   astrocytes and oligodendrocytes). Neural cells of the peripheral nervous system also include many different types of neurons and glial cells. Peripheral neural cells differentiate from transient embryonic precursor cells termed neural crest cells, which arise from the neural tube. Neural crest cells are also precursor cells to non-neural cells, including melanocytes, cartilage and connective tissue of the 15   head and neck, and cells of cardiac outflow septation (Anderson, 1989).

In the human and in other mammals, formation of the blastocyst, including development of ICM cells and their progression to pluripotent cells of the primitive ectoderm, and subsequent differentiation to form the embryonic germ layers and differentiated cells, follow a similar developmental process.

20   Pluripotent cells can be isolated from the preimplantation mouse embryo as embryonic stem (ES) cells. ES cells can be maintained indefinitely as a pluripotent cell population *in vitro*, and, when reintroduced into a host blastocyst, can contribute to all adult tissues of the mouse including the germ cells. ES cells, therefore, retain the ability to respond to all the signals that regulate normal mouse 25   development. EPL cells are a separate population of pluripotent cells distinct from ES cells. EPL cells are equivalent to early primitive ectoderm cells of the post-implantation embryo, and can be maintained, proliferated and differentiated in a controlled manner in vitro. EPL cells and their properties are described in International patent application WO99/53021.

populations such as those in embryoid bodies of this type are generally unlikely to be suitable for therapeutic or commercial use.

Selection procedures have been used to obtain cell populations enriched in neural cells from embryoid bodies. These include manipulation of culture
5   conditions to select for neural cells (Okabe et al, 1996), and genetic modification of ES cells to allow selection of neural cells by antibiotic resistance (Li et al, 1998).

In these procedures the differentiation of pluripotent cells *in vitro* does not involve biological molecules that direct differentiation in a controlled manner. Hence homogeneous synchronous, populations of neurectoderm cells with
10   unrestricted neural differentiation capability are not produced, restricting the ability to derive essentially homogeneous populations of partially differentiated or differentiated neural cells.

Chemical inducers such as retinoic acid have also been used to form neural lineages from a variety of pluripotent cells including ES cells (Bain et al, 1995).
15   However the route of retinoic acid–induced neural differentiation has not been well characterised, and the repetoire of neural cell types produced appears to be generally restricted to ventral somatic motor, branchiomotor or visceromotor neurons (Renoncourt et al, 1998).

In summary it has not been possible to control the differentiation of
20   pluripotent cells *in vitro*, to provide homogeneous, synchronous populations of neurectoderm cells with unrestricted neural differentiation capacity. Similarly methods have not been developed for the derivation of neurectoderm cells from pluripotent cells, in a manner that parallels their formation during embryogenesis. These limitations have restricted the ability to form essentially homogeneous,
25   synchronous populations of partially differentiated and terminally differentiated neural cells *in vitro*, and have restricted their further development for therapeutic and commercial applications.

Neural stem cells and precursor cells have also been derived from foetal brain and adult primary central nervous system tissue in a number of species,

neurectoderm in vivo. The neurectoderm is formed in response to molecules of biological origin and has apparently unrestricted neurectoderm differentiation capability.

As used herein, the term "neurectoderm" refers to undifferentiated neural
5   progenitor cells substantially equivalent to cell populations comprising the neural plate and/or neural tube. Neurectoderm cells referred to herein retain the capacity to differentiate into all neural lineages, including neurons and glia of the central nervous system, and neural crest cells able to form all cell types of the peripheral nervous system.

10 The neurectoderm cells so formed may be characterised as "early", for example the neurectoderm cells exhibit neural plate-like characteristics.

This is indicated by upregulation of expression of *Gbx2*, an early neurectoderm marker.

In a preferred aspect, the neurectoderm cells may be further cultured in a
15 suitable culture medium while neurectoderm cells are formed that may be characterised as "late", for example the neurectoderm cells exhibit neural tube-like characteristics.

This is indicated by down regulation of *Gbx2*.

By the term "suitable culture medium" as used herein we mean a culture
20 medium which is suitable for culturing neurectoderm cells. Desirably the culture medium excludes foetal calf serum (FCS). Desirably the culture medium does not include the conditioned medium as hereinbefore described.

Accordingly in a preferred embodiment of this aspect of the present invention, the method includes further providing a suitable culture medium as
25 hereinbefore defined, and
further culturing the early neurectoderm cells in the presence of the suitable culture medium while late neurectoderm cells are formed.

example, EPL cells may be generated in adherent culture or as cell aggregates in suspension culture. It is particularly preferred that the EPL cells are produced in suspension culture in a culture medium such as Dulbecco's Modified Eagles Medium (DMEM), supplemented with the biologically active factor etc. It is also 5 preferred that there is little or no disruption of cell to cell contact (i.e. trypsinisation).

The conditioned medium utilised in the method according to the present invention is described in International patent application WO99/53021, the entire disclosure of which is incorporated herein by reference.

10 The term "conditioned medium" includes within its scope a fraction thereof including medium components below approximately 5 kDa, and/or a fraction thereof including medium components above approximately 10 kDa

Preferably the conditioned medium is prepared using a hepatic or hepatoma cell or cell line, more preferably a human hepatocellular carcinoma cell 15 line such as Hep G2 cells (ATCC HB-8065) or Hepa-1c1c-7 cells (ATCC CRL-2026), primary embryonic mouse liver cells, primary adult mouse liver cells, or primary chicken liver cells, or an extraembryonic endodermal cell or cell line such as the cell lines END-2 and PYS-2. However, the conditioned factor may be prepared from a medium conditioned by liver or other cells from any appropriate 20 species, preferably mammalian or avian. The conditioned medium MEDII is particularly preferred.

As stated above, a neural inducing extract from the conditioned medium may be used in place of the conditioned medium. Optionally, the neural inducing extract does not include the biologically active factor conditioned medium or the 25 large or low molecular weight component thereof. The term "neural inducing extract" as used herein includes within its scope a natural or synthetic molecule or molecules which exhibit(s) similar biological activity, e.g. a molecule or molecules which compete with molecules within the conditioned medium that bind to a receptor on EPL cells responsible for neural induction.

After day 3, the conditioned medium is preferably replaced with a suitable culture medium as hereinbefore described.

It is optional that the suitable culture medium also includes a growth factor from the FGF family. The concentration of the growth factor from the FGF family is preferably in the range approximately 1 to 100 ng/ml, more preferably approximately 5 to 50 ng/ml. When FGF4 or FGF2 is used, its concentration is preferably approximately 20 ng/ml.

In a further preferred form of this aspect of the invention, the method includes the further step of

identifying the neurectoderm cells by procedures including gene expression markers, morphology and differentiation potential.

The conversion of EPL cells to neurectoderm cells is characterised by
down regulation of expression of *Oct4* relative to embryonic stem (ES) cells;and absence of expression of *brachyury*; and one or more of
up regulation of expression of N-Cam and nestin;
up regulation of expression of *Sox1* and *Sox2*; and
initial up regulation of expression of *Gbx2*, followed by down regulation thereof as neurectoderm cells persist.

In particular the upregulation of expression of *Gbx2* is indicative of neurectoderm cells having neural plate-like characteristics.

The subsequent downregulation of *Gbx2* is indicative of cells having neural tube-like characteristics.

Preferably the neurectoderm cell exhibits three of the above characteristics, more preferably four.

For example, the following gene expression profile is evident in neurectoderm cells according to the present invention.

12

In particular the neurectoderm cell exhibits initial upregulation of *Gbx2* indicative of early neurectoderm cells having neural plate-like characteristics.

The neurectoderm cell exhibits subsequent down regulation of *Gbx2* indicative of late neurectoderm cells having neural tube-like characteristics,

5   the late neurectoderm being further characterised by the substantial absence of patterning marker expression;
and up regulation of neural genes

The neurectoderm cell according to the present invention has the capacity to differentiate into all neural lineages.

10   As discussed below, the neurectoderm cell according to the present invention may disperse and differentiate *in vivo* following brain implantation. In particular following intraventricular implantation, the cell is capable of dispersing widely along the ventricle walls and moving to the sub-ependymal layer. The cell is further able to move into deeper regions of the brain, including into the 15 uninjected side of the brain into sites that include the thalamus, frontal cortex, caudate putamen and colliculus.

During embryogenesis *in vivo,* neurectoderm cells respond to positional signals that lead to the formation of specific differentiated neural cell types. As part of the response to positional signals, position-dependent gene expression is 20 initiated in neurectoderm cells in restricted locations along the rostro-caudal and dorso-ventral axes within the developing nervous system. These genes serve as markers of positional responses, indicative of future developmental restriction.

Surprisingly, neurectoderm cells according to the present invention do not express the patterning markers *HoxB1, Hoxa7, Krox20, Nkx2.2* and *Shh.* This 25 may distinguish neurectoderm cells produced according to the present invention from neurectoderm cells produced from other sources including for example foetal and adult primary tissues including neural stem cells. Accordingly, the potential for neural development of these cells is expected to be unrestricted, and thus

neurectoderm cells produced as described above; and

a suitable culture medium as hereinbefore described;

further culturing the neurectoderm cells in the culture medium to form aggregates of neurectoderm cells.

5   Preferably the further culturing step begins at day 3 or later.

In a further aspect of the invention there is provided methods for producing differentiated or partially differentiated cells from neurectoderm cells, which method includes

providing

10   neurectoderm cells as hereinbefore described, and

a suitable culture medium;

further culturing the cells in the presence or absence of a growth factor from the FGF family, and optionally in the presence of additional growth factors and/or differentiation agents, to produce the differentiated or partially differentiated cells.

15   Preferably the cells produced are cells selected from the group consisting of neuronal cell precursors, neural crest cells, glial cell precursors, or differentiated neurons or glial cells.

The neurectoderm cells may differentiate to form neuronal cells with high frequency.

20   The step of further culturing the neurectoderm cells in the presence or absence of a growth factor from the FGF family and in the presence of additional growth factors and/or differentiation agents, may be conducted in any suitable manner. Preferably the cellular aggregates or explants cultured in the presence or absence of a growth factor from the FGF family in the presence of additional
25 growth factors and/or differentiation agents,. For example, differentiated or partially differentiated cells may be generated in adherent culture or as cell aggregates in suspension culture. Preferably the cells are cultured for approximately a further 3 hours to 10 days, more preferably approximately 1 to 6 days.

EGF growth factor; and

in a second stage, in the presence of a PDGF growth factor and in the substantial absence of EGF, FGF and laminin.

For example neurectoderm aggregates or explants are preferably grown in adherent culture in medium that includes a member of the FGF family (eg; FGF2 or FGF4 10 ng/ml) and EGF (eg; 20 ng/ml) and laminin (eg; 1 to 3 µg/ml) for ~3 d then cultured for further 2 to 3 d in the absence of EGF, FGF and laminin and presence of PDGF (eg PDGF-AA, 10 ng/ml).

The conversion of neurectoderm cell to glial cells is characterised by a change in morphology and up regulation of expresion of the cell surface marker GFAP.

Accordingly, in a further aspect of the present invention, there is provided a partially differentiated neuronal cell, or a terminally differentiated neuronal cell, a partially differentiated neural crest cell, or a terminally differentiated neural crest cell, a partially differentiated glial cell, or a terminally differentiated glial cell, produced by the method described above or derived from neurectoderm cells as hereinbefore described.

Preferably the cells are present as a predominantly homogeneous population.

In a preferred aspect there is now provided

a substantially homogeneous neural crest cell population obtained *in vitro* exhibiting two or more of the following characteristics:

neural crest cell morphology;

cell migration; and

expression of *Sox10*.

In a further preferred aspect there is provided

a substantially homogeneous glial cell population obtained in vitro exhibiting one or both of the following characteristics:

providing

a source of genetically modified pluripotent cells;

a source of a biologically active factor including

a low molecular weight component selected from the group
consisting of proline and peptides including proline and functionally
active fragments and analogues thereof; and

a large molecular weight component selected from the group
consisting of extracellular matrix portions and functionally active
fragments or analogues thereof, or the low or large molecular weight
component thereof;

a conditioned medium as hereinbefore defined; or an extract
therefrom exhibiting neural inducing properties;

contacting the pluripotent cells with the source of the biologically active
factor, or the large or low molecular weight component thereof, to produce
genetically modified early primitive ectoderm-like (EPL) cells; and

contacting the genetically modified EPL cells with the conditioned medium
or extract to produce genetically modified early neurectoderm cells.

The method preferably further includes providing a suitable culture medium
as hereinbefore defined, and

further culturing the early neurectoderm cells in the presence of the suitable
culture medium for a time sufficient to form genetically modified late neurectoderm
cells.

More preferably, the further culturing step is conducted in the presence of a
growth factor from the FGF family.

Modification of the genes of these cells may be conducted by any means
known to the skilled person which includes introducing extraneous DNA, removing
DNA or causing mutations within the DNA of these cells. Modification of the
genes includes any changes to the genetic make-up of the cell thereby resulting in
a cell genetically different to the original cell.

20

cells can be implanted, thus allowing appropriate delivery of therapeutically active molecules.

• use as a source of cells for reprogramming. For example karyoplasts from neurectoderm or their differentiated or partially differentiated progeny may be reprogrammed by nuclear transfer. Cytoplasts from neurectodermal cells may also be used as vehicles for reprogramming so that nuclear material derived from other cell types are directed along neural lineages. Alternatively neural stem cells may be reprogrammed in response to environmental and biological signals that they are not normally exposed to. For example the differentiation of murine neural stem cells is redirected to form haematopoietic cells (cells of mesodermal lineage), when injected into the bone marrow (eg; Bjornson et al, 1999). Hence neurectoderm cells described herein are potentially capable of forming differentiated cells of non-neural lineages, including cells of mesodermal lineage, such as haematopoietic cells and muscle. Reprogramming technology using neural cells potentially offers a range of approaches to derive cells for autologous transplant. In one approach karyoplasts from differentiated cells are obtained from the patient, and reprogrammed in neurectoderm cytoplasts to generate autologous neurectoderm. The autologous neurectoderm cells or their differentiated or partially differentiated progeny could then be used in cell therapy to treat neurodegenerative diseases. See Australian provisional patent applications PR1348 and PR2126, the entire disclosures of which are incorporated herein by reference. Alternatively neurectoderm could be further dedifferentiated to a pluripotent state by fusion with pluripotent cytoplasts, and subsequently directed along alternative differentiation pathways to form cells of mesodermal or endodermal lineage.

• use in pharmaceutical screening for therapeutic drugs that influence the behaviour of neurectoderm cells and their differentiated or

In the figures:

Figure 1

Analysis of EB[4] and EBM[4]

A-D. 7 µm sections of paraffin embedded EBM[4] (A, B) and EB[4] (C, D) stained with haematoxylin;eosin (A, C) and Hoescht 22358 (B, D). E. 20 µg RNA from EB[2-4] and EBM[2-4] was analysed for the expression of *Fgf5*, *brachyury*, *Oct4* and *mGAP* by Northern blot analysis. *Fgf5* transcripts were 2.7 and 1.8 kb (Herbert et al., 1990), *brachyury* 2.1 kb (Lake et al., 2000), *Oct4* 1.55 kb (Rosner et al., 1990) and *mGAP* 1.5 kb. F-K. In situ hybridisation analysis of EBM[4] (F, G, H) and EB[4] (I, J, K) with deoxygenin labelled antisense probes for *Oct4* (F, I), *Fgf5* (G, J) and *brachyury* (H, K).

Figure 2

Differentiation of EBM

Morphology of EBM[7] (A) and EBM[9] (B). C. 7 µm section of paraffin embedded EBM[9] stained with haematoxylin. D. 20 µg RNA from EB[4-8] and EBM[4-8] was analysed for the expression of *Oct4* and *mGAP*. *Oct4* transcripts were 1.55 kb (Rosner et al., 1990) and *mGAP* 1.5 kb. E. In situ hybridisation analysis of seeded EBM[7] two days post-seeding with deoxygenin labelled antisense probes for *Oct4*.

Figure 3

ES cells differentiated as EBM form neurectoderm

A, B. In situ hybridisation analysis of seeded EBM[7] two days post-seeding with deoxygenin labelled antisense probes for *Sox1* (A) and *Sox2* (B). C, D. Immunohistochemical analysis of seeded EBM[7] two days post-seeding with antibodies directed against nestin (C) and NCam (D). Nestin immunoreactivity was

24

expression of *Sox1* (A) and *Sox2* (B). Stained EBM9 were embedded in paraffin wax and 7 μm sections analysed for homogeneity of gene expression. **C.** Flow cytometry of dissociated EBM[10] and EB[10] analysed for expression of the cell surface antigen NCam. NCam positive cells were identified by comparison with
5   cell populations that had been stained with secondary antibody only (data not shown). Cells staining with intensities greater than the secondary antibody only control were determined to be expressing NCam, and are indicated by the bar.

Figure 7

Gbx2 is temporally regulated during EBM differentiation

10   In situ hybridisation analysis of seeded EBM[7] 1 (A, D), 2 (B, E) and 3 (C, F) days post-seeding with deoxygenin labelled antisense probes for *Sox1* (A, B, C) and *Gbx2* (D, E, F).

Figure 8

Expression of positionally specified genes in EBM[9]

15   cDNA was synthesised from 1 μg of total RNA isolated from EB[9] (EB), EPLEB[9] (EPLEB), EBM[9] (EBM) and a day 10 mouse embryo (day 10) and used as a template for PCR analysis of the genes denoted. Expression of Actin was used as a positive control. Primer sequences and product sizes can be found in example 3.

20 **Figure 9**

ES cell-derived neurectoderm can be directed down neural crest and glial lineages

A-D. EBM[9] explants were seeded onto cellular fibronectin treated tissue culture plasticware in medium supplemented with 25 nM staurosporine/ 0.1%
25 DMSO (A, C, D) or 0.1% DMSO alone (B). Cultures were examined after 3 (A, B)

cell differentiation. The brain section was 0.5mm thick and the field of view is 216x144μm.

Figure 13

GFP positive cells at 16 weeks in rat brain

5   Confocal image of GFP positive cells located in the thalamus of the rat brain injected with EBM^7 at 16 weeks. The brain section was 0.5mm thick and the field of view is 216x144μm.

Figure 14

The distribution of GFP positive cells (EBM^7 and EBM^{10}) in the rat brain over
10   **time**

The black represents areas where cells were identified up to 4 weeks post injection and the white represents regions of the brain where the cells were located at times up to 16 weeks post injection. Note that, the two dimensional slice through the rat brain does not depict all the labeled regions.

15   **Figure 15**

Cell differentiation at 2 weeks in rat brain

Immunohistochemical analysis of cells in serial sections (7μm) of rat caudate putamen 14 days after EBM^7 implantation. Sections were stained for the expression of nestin (A), NF200 (B), GFP (C) and GFAP (D). The arrows
20   represent regions of GFP + NF200 co-expression (white arrows) and GFP + GFAP co-expression (black arrow). Pictures were taken at 400 times magnification.

filter.

Formation of cell aggregates

All cell aggregates were formed from single cell suspensions (1 x 10^5 cells/ml) of ES or EPL cells cultured in bacterial petri dishes. ES cell and EPL cell
5   embryoid bodies (EB and EPLEB respectively) were formed as described in Lake et al. (2000). EBM, cell aggregates formed and maintained in MEDII, were formed from ES cells aggregated in IC:DMEM (DMEM (Gibco BRL #12800) with 10% foetal calf serum (FCS; Commonwealth Serum Laboratories), 40 mg/ml gentamycin, 1 mM L-glutamine and 0.1 mM ß-mercaptoethanol (ß-ME))
10   supplemented with 50% MEDII. Aggregates were divided 1 in 2 on days 2 and 4, and medium was changed on days 2 and 4 and then daily until collection. In early experiments 10-20 ng/ml FGF4 was added to the medium from day 4, however this did not influence the outcome of differentiation and was omitted in later experiments. The time in days from formation of aggregates was denoted by
15   superscript with the day of formation denoted as day 0. For example, EBM 5 days after formation are represented as EBM^5.

For continued suspension culture of EB and EBM, aggregates on day 7 were transferred to serum free medium (50% DMEM, 50% Hams F12 (Gibco BRL # 11765) supplemented with 1 x ITSS supplement (Boehringer Mannhiem) and 10
20   ng/ml FGF2 (Peprotech Inc.)).

For adherent culture, aggregates were seeded onto gelatin treated tissue culture grade plasticware (Falcon) on day 7 of development in 500 µl DMEM supplemented with 10% FCS (Commonwealth serum Laboratories). On day 8 medium was removed and replaced with 50% DMEM, 50% Hams F12
25   supplemented with 1 x ITSS (Boehringer Mannhiem).

Analysis of differentiation potential of cells within cellular aggregates

EB^7 and EBM^7 were seeded as described above and assessed on days 8, 10, 12 and 14 for the presence of neurons, identified morphologically by the

of Developmental Genetics, National Institute for Medical Research, Mill Hill, London). Transcripts were generated from *AccI* and *XbaI* linearised plasmid transcribed with T3 (anti-sense) and T7 (sense) RNA polymerases respectively.

Histological analysis

5   EB[4] and EBM[4] were fixed with 4% PFA for 30 minutes before embedding in paraffin wax and sectioning as described in Hogan et al., 1994. 7 μm sections were stained with haematoxylin:eosin as described by Kaufman, 1992 or with Hoescht 22358 (5μg/ml in PBS; Sigma) for 5 minutes.

Immunohistochemical Analysis

10   Cellular aggregates were fixed in 4% paraformaldehyde in PBS for 30 minutes, and dehydrated in sequential 30 minute washes in 50% ethanol and 70% ethanol. Cells were rehydrated to PBS and permeabilised with RIPA buffer (150 mM NaCl; 1% NP-40; 0.5% NaDOC; 0.1% SDS) for 30 minutes, washed in PBS and blocked in the appropriate blocking buffer as described below for 30 minutes.
15   Primary antibodies, diluted in the appropriate blocking buffer, were added and incubated overnight at 4°C. After washing in PBS, aggregates were incubated with alkaline phosphatase conjugated, species specific secondary antibodies directed against the primary antibodies in 100 mM Tris.Cl (pH7.5), 100 mM NaCl, 0.5% blocking reagent (Boehringer Mannheim). For alkaline phosphatase conjugated
20   secondary antibodies, cellular aggregates were washed in Buffer 2 (100 mM Tris.Cl (pH 9.5), 100 mM NaCl, 5 mM MgCl$_2$) and antibody conjugates were detected enzymatically with NBT and BCIP (both Boehringer Mannheim) made up in Buffer 2 according to the manufacturers instructions. Aggregates were visualised on a Nikon TE300 using Hoffmann interference contrast optics. For
25   FITC conjugated secondary antibodies, cellular aggregates were washed in PBS and mounted in 80% glycerol containing 5 mg/ml propyl gallate (Sigma). Aggregates were examined on a Nikon TE300 microscope using a FITC filter.

Nestin: Blocking buffer: 10% goat serum, 2% BSA in PBS. Primary antibody: Developmental Studies Hybridoma Bank, reference Rat 401, used at a

ES cells were aggregated in medium supplemented with 50% MEDII (EBM) and compared to EB development. After 4 days cellular aggregates formed in the presence of MEDII (EBM^4) could be distinguished from EB^4 by morphology. Histological analysis of sectioned EB^4 and EBM^4 showed EBM^4 to comprise a
5 multi-cell layer of uniform thickness surrounding a single, internal area of cell death indicated by the presence of pyknotic nuclei (Figure 1A, B). No morphologically distinct outer layer of cells reflecting the presence of extra-embryonic endoderm could be detected at this or later stages of EBM development. In contrast, EB^4 were internally disorganised with sporadic, multiple
10 foci of cell death dispersed throughout the aggregates (Figure 1C, D). An outer layer of extraembryonic endoderm was apparent at low levels in EB^4 and at higher levels in more advanced EB (data not shown).

EB$^{2-4}$ and EBM$^{2-4}$ were analysed by Northern blot (Figure 1E) for the expression of Oct4, a marker gene for pluripotent cells (Scholer et al., 1990), and
15 Fgf5, a gene up-regulated in pluripotent cells upon primitive ectoderm formation (Haub and Goldfarb, 1991). Oct4 expression was maintained at high levels throughout these stages of EBM development indicating that pluripotent cell differentiation had not commenced within these aggregates. High level Oct4 expression in EBM^4 was accompanied by elevated Fgf5 expression, indicating that
20 the pluripotent cells had formed primitive ectoderm. In contrast, highest levels of Oct4 and Fgf5 expression in EB were observed at days 2-3 and day 3 respectively. Downregulation of both genes in EB^4 indicated that pluripotent cells within these aggregates had differentiated.

The distribution of pluripotent cells within aggregates was investigated by
25 wholemount in situ hybridisation of EB^4 and EBM^4 with Oct4 and Fgf5 antisense probes. Homogeneous expression of Oct4 (Figure 1F) and Fgf5 (Figure 1G) within and between individual EBM^4 aggregates was consistent with the deduced cellular homogeneity of primitive ectoderm within these aggregates and persistence of pluripotent cells to day 4. This contrasted with patchy expression of these markers
30 within and between individual EB^4 aggregates (Figure 1. I, J), consistent with the variable onset and progression of pluripotent cell differentiation within EB

34

2 days of culture formed a population in which >95% aggregates comprised a single stratified epithelial sheet (Figure 2B, C). Cellular aggregates of similar morphology were not detected within the EB[7] or EB[9] populations although equivalent cell layers could be detected within a proportion of individual

5   aggregates (data not shown).

Northern blot analysis of EB[4-8] and EBM[4-8] showed a down-regulation of Oct4 in both populations (Figure 2D) suggesting differentiation of the pluripotent cells within both populations of aggregates. However, while Oct4 was undetectable in EB after day 5, a low but consistent level of Oct4 expression, 4.2-

10   fold lower than EBM[4], could be detected in EBM on all days of development after day 5. EBM[7] were seeded onto gelatin treated tissue culture grade plasticware in DMEM containing 10% FCS and analysed after a further 24 hours culture (EBM[8]) by wholemount in situ hybridisation with an Oct4 anti-sense probe. This analysis failed to detect cells expressing Oct4 at levels equivalent to pluripotent cells

15   (Figure 2E), which suggested that the Oct4 expression detected by Northern blot analysis represented low level expression by the majority of cells within the population and not expression by a small population of residual pluripotent cells within the aggregates.

As the morphology of EBM[9] was clearly reminiscent of neurectoderm

20   (Figure 2C), the expression of a number of neural markers was analysed. EBM[7] were seeded onto gelatin treated tissue culture grade plasticware in DMEM containing 10% FCS and the medium was changed to 50% DMEM:50% Hams F12 supplemented with ITSS and 10 ng/ml FGF2 after 16 hours. These aggregates were analysed by in situ hybridisation for the expression of Sox1 and

25   Sox2. Sox1 has been shown to delineate the neural plate and is expressed by all undifferentiated neural cells, while Sox2 shows a similar expression pattern but is expressed earlier in embryogenesis (Pevney et al., 1998). Seeded aggregates were also analysed by immunohistochemistry using antibodies directed against nestin, a neurofilament protein expressed in neural progenitor cells (Zimmerman

30   et al., 1994) and N-Cam, a cadherin expressed within the neural system by primitive neurectoderm, neurons and glia (Rutihauser, 1992). Widespread

expressing EGFP were differentiated as EB or EBM. Individual cell aggregates were seeded on day 7 and assessed for the formation of neurons on day 14 (Figure 4). All clonal lines formed neurons when differentiated as either EB or EBM. When differentiated as EB the formation of neurons varied between 4 and

5   28% of bodies, with an average of 15.64% +/- 2.54. This indicates that the uncontrolled differentiation of pluripotent cells in EB is not consistent between different clonal ES cell isolates. All clonal lines responded to MEDII as previously described by formation of neurectoderm-containing aggregates. Neuron formation was increased to >80% of aggregates, with an average of 92.13% +/- 1.944. This

10   result suggests that response to MEDII by differentiation to ectodermal lineages is an inherent property of ES cells and not restricted to a subpopulation within the ES cell population. Further, MEDII-directed differentiation of ES cells as EBM overcame the inherent variability associated with EB differentiation and resulted in uniform, high level production of neurectoderm and neurons.

15   *EPL cells differentiate to form neurons in response to MEDII*

It has been previously reported that EPL cells form neurons poorly, if at all, when differentiated as EB but form elevated levels of nascent and differentiated mesoderm (see International patent application PCT/AU99/00265, above). This has been interpreted as reflecting disrupted signalling from visceral endoderm or

20   visceral endoderm-derived ECM (Lake et al, 2000). EPL cells were formed from ES cells as described, and aggregated and cultured in suspension for 7 days in either IC:DMEM (EPLEB) or IC:DMEM supplemented with 50% MEDII (EPLEBM). On day 7, individual EPL cell embryoid bodies were seeded onto gelatin treated tissue culture plasticware in IC:DMEM. On day 8 the medium was changed to

25   DMEM:F12 and embryoid bodies were cultured for a further 4 days before microscopic inspection for the presence of beating cardiocytes and neurons.

As shown in figure 5A, EPL cell embryoid bodies formed beating cardiocytes efficiently (35.25%), consistent with previous reports and gene expression (Lake et al., 2000). In contrast, EPL cell embryoid bodies cultured in

30   the presence of 50% MEDII exhibited drastically lower levels of beating cardiocyte formation (0.9%). Aggregation and differentiation of EPL cells in the presence of

derived neural progenitors

Methods

Cell culture and gene expression analysis

EB and EBM were aggregated and cultured as described in example 1.
5   Gene expression analysis was as described in example 1. EBM which had been
analysed by whole mount in situ hybridisation staining were prepared for
histochemical analysis as follows. Stained EBM were fixed in 4% PFA overnight,
washed several times with PBS, 0.1% Tween-20, treated with 100% methanol for
5 minutes and then isopropanol for 10 minutes. Bodies were then treated and
10   embedded as described in Hogan et al. (1994).

DIG labelled *Gbx2* riboprobes were generated from pG290 which contains
a 290 bp PCR fragment from base 780 to base 1070 of the *Gbx2* cDNA
(Chapman and Rathjen, 1995) cloned into pGEMT-easy (Promega). Antisense
and sense probes were transcribed from *SalI* or *StyI* cut pG290 with T7 or T3 RNA
15   polymerase respectively.

Flow Cytometry analysis

EB^{10} and EBM^{10} were collected and washed in PBS, then disassociated by
incubating for 5 minutes in 0.5 mM EDTA/PBS followed by vigorous pipetting and
agitation to a single cell suspension. Cells were washed several times in PBS
20   before fixation with 4% PFA for 30 minutes. Cells were washed with 1% BSA/PBS,
resuspended at 1×10^6 cells/ml, and incubated with antibody directed against N-
Cam (Santa Cruz Biotech, SC-1507) at a dilution of 1:2 for 1 hour. Cells were
washed with 1% BSA/PBS before incubation with FITC conjugated goat anti-
mouse IgM (μ-specific: Sigma) used at a concentration of 1:100. FITC conjugated
25   goat anti-mouse IgM was pre-adsorbed for 1 hour in 1% BSA/PBS before use.
Cells were washed in PBS and fixed in 1% PFA for 30 minutes. Data was
collected on 1×10^4 cells on a Benton Dickonson FACScan and analysis

1997). With continued development the neural plate folds at the midline and the outer edges close to form the neural tube. *Sox1* expression is maintained after tube closure but *Gbx2* expression is down regulated in the majority of cells of the neural lineage and persists only in a restricted population of cells at the mid-

5   brain/hind-brain boundary (Wassarman et al., 1997).

Wholemount in situ hybridisation of seeded EBM[8], EBM[9] and EBM[10] was used to investigate the temporal regulation of *Sox1* and *Gbx2* in during EBM progression. At day 8, *Sox1* was expressed in approximately 50% of the cells within the seeded aggregates (Figure 7A). The extent of expression was increased

10   in EBM[9], and evident in the majority of cells within the aggregates on both day 9 and 10 (Figure 7 B, C), indicating homogeneous formation of neurectoderm. *Gbx2* was also expressed in approximately 50% of the cells within the seeded aggregates at day 8, but was less abundant in EBM[9], and was virtually undetectable in EBM[10] (Figure 7 D,E,F). The loss of *Gbx2* expression in

15   aggregates in which *Sox1* expression persists recapitulates the temporal regulation of this gene in the developing neural tube of the embryo. Rapid downregulation of *Gbx2* expression indicates relative synchrony of the EBM differentiation system, and suggests EBM[8] represent cells equivalent to the time of neural tube closure in vivo..

20   **Conclusion**

Cellular analysis of gene expression indicates that differentiation of ES cells as EBM results in the formation of a homogeneous population of neural progenitors. Temporal regulation of gene expression indicated relative synchrony of differentiation within and between EBM aggregates, and was conserved in

25   many aspects with formation of the ectodermal/neurectodermal lineages during mammalian embryogenesis. EBM differentiation therefore recapitulates progressive formation of neural plate and neural tube, progenitors for the entire nervous system, from pluripotent cells in the mammalian embryo.

42

Nkx2.2　　　　(514bp)

(5' CTCTTCTCCAAAGCGCAGAC 3'; 5' AACAACCGTGGTAAGGATCG 3'),

Krox20　　　(502bp)

(5' GGAGGGCAAAAGGAGATACC 3'; 5' GGTCCAGTTCAGGCTGAGTC 3'),

5　*Pax3*　　　　(502 bp)

(5' CGTGTCAGATCCCAGTAGCA 3'; 5' CCTTCCAGGAGGAACTACCC 3'),

Pax6　　　　(500 bp)

(5' AGTTCTTCGCAACCTGGCTA 3'; 5' TGAAGCTGCTGCTGATAGGA 3').

PCR products were analysed on 2% agarose gels and visualised with

10　ethidium bromide.

Results

In vivo the neural tube acquires region specific gene expression with respect to both the rostral/caudal and dorsal/ventral axes, indicative of restricted developmental fate. Expression of neural tube markers expressed in the neural

15　tube shortly after closure in restricted anterior, posterior and ventral domains was analysed in EBM[9], which expresses *Sox1* and *Sox2* but not *Gbx2*, equivalent to closed neural tube in vivo. The ectodermal expression patterns of the analysed genes are described in table 1. Gene expression in EBM[9] was analysed by RT-PCR or in situ hybridisation (*Gbx2*) and compared to EB[9] and EPLEB[9], which

20　comprise a mixed population of cells containing ectoderm and mesoderm, and a mesoderm-enriched, ectoderm deficient (International patent application PCT/AU99/00265, above) population respectively. RNA from d10 embryos was used as a positive control.

As shown in figure 8, the expression of genes marking presumptive

25　forebrain (*Nkx2.2*), individual rhombomeres of the hindbrain (*HoxB1*, *Krox20*), midbrain/hindbrain boundary (*Gbx2*), posterior ectoderm and trunk (*Hoxa7*), and ventral neural tube (*Shh*) was not detected in EBM[9]. Furthermore, the absence of *Shh* expression that is required for specification of ventral identity in the neural tube (Echelard et al., 1993), indicates that the signalling pathways leading to

Conclusion

Analysis of neural tube markers with spatially restricted expression in EBM indicated that the neural progenitor cells within these aggregates have not acquired positional specification. Further, signalling systems required for positional 5 specification are not operative. This suggests that neural progenitor cells formed from pluripotent cells in response to MEDII are unlikely to be developmentally restricted. EBM therefore provide a superior system for the generation of neural progenitors from pluripotent cells compared to chemical induction or differentiation within EB in which positionally restricted genes are expressed.

10   **EXAMPLE 4**

Differentiation of ES cell-derived neurectoderm can be directed to neural crest or glial lineages in response to exogenous signalling

Methods

Cell culture, in situ hybridisation and immunohistochemistry were as 15 described in example 1.

Sox 10 probes were transcribed from pSox10E.1 (obtained from Dr. Peter Koopman, IMB, Brisbane, Australia). Anti-sense and sense probes were transcribed from HindIII or BamHI cut pSox10E.1 with T7 or T3 RNA polymerase respectively.

20   Anti-glial fibrillary acidic protein (GFAP: Sigma #G9269) was used at a dilution of 1/1000 and detected with alkaline phosphatase conjugated goat anti-rabbit IgG (ZyMax grade, Zymed Laboratories Inc.) used at a dilution of 1/1000. Cells were blocked for 30 minutes in 10% goat serum, 2% BSA in PBS.

Neural crest formation

25   EBM[9] were collected, washed in PBS, treated with 0.5 mM EGTA pH 7.5 for

surrounded by a halo of differentiating cells (Fig. 8A) which appeared morphologically indistinguishable from avian neural crest cells produced from avian neural tube in response to staurosporine (Newgreen & Minichiello, 1996). The phenotypic alteration induced by staurosporine was homogeneous across the

5 population of aggregates, and was not observed in EBM explants cultured in medium containing 0.1% DMSO (Figure 8B). This differentiation was observed in the presence of 1 nM to 100 nM staurosporine, although uniform differentiation required concentrations greater than 10 nM (data not shown). After 48 hours culture, EBM explants were analysed by in situ hybridisation for expression of

10 Sox10 (Figure 8C) which is up regulated on the formation of mouse neural crest in vivo (Southard-Smith et al., 1998). Sox10 expression was observed in all cells formed in response to staurosporine, but not in those cultured in medium containing 0.1% DMSO.

ES cell derived neural stem cells have been shown to differentiate to glial

15 lineages in response to sequential culture in EGF/laminin and PDGF-AA (Brustle et al., 1999). EBM[9] explants were cultured in medium containing FGF2 (10 ng/ml), EGF (20 ng/ml) and laminin (1 μg/ml). After 5 days EGF and laminin were omitted from the medium and PDGF-AA was added to a concentration of 10 ng/ml for a further 2-3 days. Cells were not trypsinised or triturated during differentiation.

20 Cultures were analysed by immunohistochemistry for the expression of glial fibrillary acidic protein (GFAP), a marker expressed by both glial precursors and differentiated astrocytes (Landry et al., 1990). Differentiation of EBM[9] explants in response to EGF/laminin and PDGF-AA follows a homogeneous morphological progression depicted in Figure 8E-G. >95% of differentiated cells formed from

25 EBM explants using this protocol expressed GFAP (Figure 8H), indicating homogeneous differentiation to cells of the glial lineage.

Conclusion

Differentiation of neurectoderm derived from pluripotent cells in response to MEDII can be directed to neural crest or glial fates by the additional of biologically

30 relevant exogenous signalling molecules. This indicates that neurectoderm derived by differentiation of pluripotent cells in response to MEDII has

no more than 2 hours before implantation.

Injection procedure

Sprague Dawley rats no older than 8 hours were chilled on ice for up to 20 minutes to reduce their metabolic rate and reduce movement. 2μl of cell 5   suspension or DMEM was injected into the left lateral ventricle.

A sterile 5μl positive displacement gas chromatography syringe (SGE, UK), modified by reducing the length of the needle to 2cm, was used for injection. Coordinates for the location of the left lateral ventricle were obtained from Paxinos et al, 1994. The needle was introduced at a 45° angle into the skull 2mm above 10 the left eye socket, to a depth of approximately 0.5cm, and the cells were implanted.   Successful injection into the lateral ventricle was identified by displacement of 2μl of clear CSF from the injection site following introduction of the cells. The left rear toe was clipped for identification purposes. The newborn rats were placed under a heat lamp for 15 minutes to reset their core temperature, 15 reunited with their mothers and observed daily.

Assessment of cellular incorporation

Rats were sacrificed by cervical dislocation at 1, 2, 4, 8 and 16 weeks after implantation of cells.

Brains were removed and fixed for 4 hours in 4% para-formaldehyde before 20 dehydration. Brains were immersed in 50% ethanol for 4 hours then 70% ethanol for 4 hours. Brains were stored at 4°C in 70% ethanol inside tissue processing cassettes (Bayer, Australia).

All brains were sectioned horizontally using a vibratome (Lancer, 1000). 0.5mm sections were visualised under the fluorescent (Nikon TE300, FITC, 25 excitation 465/95 emission 515/55nm, with the dichroic mirror set at 505nm) or confocal (Bio/Rad MRC 1000uv confocal system attached to a Nikon Diphot 3000 microscope) microscope. For confocal microscopy, excitation and emission

GFP: Blocking buffer containing primary antibody to GFP raised in mouse and used at 1 in 1000, Clonetec, USA. Secondary antibody: Anti-mouse IgG conjugated to alkaline phosphatase, 1 in 4000, Rockland, USA.

GFAP: Blocking buffer containing primary antibody to glial fibrilliary acidic

5   protein, GFAP raised in rabbit used at 1 in 500, Sigma, UK; Secondary antibody: Anti-rabbit IgG conjugated to alkaline phosphatase, 1 in 500, Zymed, USA.

Primary antibodies were added to the slices overnight at 4°C. The tissue sections were then washed 3 times for 30 minutes at room temperature with PBS, and then with buffer 1 (Tris-HCl 100mM, pH 7.5, NaCl 150mM) for 10 minutes at

10   room temperature. The secondary antibodies were diluted in buffer 1 containing 0.5% blocking powder (Roche, Germany) and added to the sections for 2 hours at room temperature. The tissue was then washed in buffer 1 twice for 15 minutes and then in buffer 2 (Tris-HCl 100mM pH9.5, NaCl 100mM, $MgCl_2$ 5mM, with 0.1% Tween 20, Sigma, UK for 10 minutes). Development solution (buffer 2 with 0.2%

15   Nitroblue tetrazolium/5-Bromo-4-chloro-4-indolyl phosphate, Roche, Germany and 5mM levamisole, Sigma, UK) was then added to the tissue and the dark purple colour was allowed to develop overnight in the dark.

Results

A total of 72 rats were used in the study and their treatment is summarised

20   in table 1.

52

After one week GFP positive cells were identified in all implanted rats, predominantly located around the implantation site as multiple clumps (~50-300 cells per clump) within the left lateral ventricle wall. Rats injected with 20,000 cells had fewer GFP positive clumps of cells compared with rats implanted with 5 200,000 cells. All brains harvested at 1 week showed no abnormal development when compared with the un-injected and DMEM injected control animals.

After 2 weeks, GFP positive cells were still present in the left lateral ventricle wall of all implanted rats, however additional regions of GFP positive cells in other sites such as the 3rd ventricle wall and the cerebral aqueducts were 10 identified, indicating that the cells had moved within the cerebrospinal fluid. Implanted cells at 2 weeks formed multiple clumps per brain, each clump consisting of approximately 50 to 300 GFP positive cells within the walls of the ventricular system (a typical clump is shown in Fig. 10). No apparent difference between the implantation of EBM^7 or EBM^{10} cells in the brain was observed at 1 15 and 2 weeks.

After 4 weeks, GFP positive cells were found in all implanted brains and they had dispersed widely along the ventricle walls. Many cells had moved into the sub-ependymal layer (Fig. 11). No difference was observed between the distribution of EBM^7 or EBM^{10} implants.

20   At 8 and 16 weeks after implantation, GFP positive cells could no longer be identified around the ventricle walls and were difficult to find. This may be due to dispersal of the cells within the brain or represent a loss of cells due to immuno rejection. In all the brains examined in both EBM^7 and EBM^{10} groups at 8 and 16 weeks, GFP positive cells were identified in deeper brain regions such as the 25 thalamus, (Fig. 12), frontal cortex, caudate putamen (Fig. 13) and colliculus, midbrain and in these sites in the un-injected right side of the brain. There were no apparent differences in the distribution of EBM^7 and EBM^{10} at either 8 or 16 weeks. The distribution of implanted GFP positive cells within rat brains over 16 weeks is shown in Fig. 14. The black areas represent the location of the GFP 30 positive cells at time points up to 4 weeks and the white at later times up to 16 weeks. The cells were initially located within the CSF, then incorporated into the

Conclusions

These data show that neural progenitors derived by differentiation of pluripotent cells in response to MEDII can incorporate, differentiate and disperse in the rat brain. The neural progenitors derived by differentiation of pluripotent cells in response to MEDII are therefore potentially of use for the replacement of damaged or dysfunctional brain cells in conditions such as Parkinson's disease, dementia, central ischaemic injury resulting from trauma or stroke, spinal injury and movement disorders.

TABLE 2

Summation of the ectodermal expression patterns of positionally specified neural markers

Gene	Ectodermal expression pattern in vivo	Reference
En1	Detected on day 8.0 of development in a neural folds at the level of the foregut pocket. Expression persists at the midbrain/hindbrain boundary	Davis and Joyner 1988
En2	as for En1	Davis and Joyner 1988
Gbx2	Pan neural expression occurs prior to neural tube closure (d 7.5). Expressed caudal to midbrain at d9.5, and later in the forebrain.	Wassarman et al. 1997
Hoxa7	Expressed in the posterior ectoderm and the trunk	Mahon et al. 1988
HoxB1	Expressed with Rhombomere 4	Studer et al 1998
Krox20	Expression is established in the early neural plate (d8.0) in a single domain and then in a second more posterior domain (d8.5). These domains coincide with the later position of rhombomeres 3 and 5 respectively.	Nieto et al. 1991

REFERENCES

Anderson D.J. (1989). The neural crest cell lineage problem: neuropoiesis? Neuron 3, 1-12.

Bain G., Kitchens D., Yao M., Huettneer JE., Gottlieb DI., (1995) Embryonic stem cells express neuronal properties in vitro. Dev Biol 168, 342-357.

Bjornson C.R., Rietze R.L., Reynolds B.A., Magli M.C. and Vescovi A.L. (1999). Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science; 283, 534-537.

Brustle O., Jones K.N., Learish R.D., Karram K., Choudhary K., Wiestler O.D., Duncan I.D. and McKay R.D. (1999). Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science. 285, 754-756.

Chapman, G. and Rathjen, P.D. (1995). Sequence and evolutionary conservation of the murine Gbx-2 homeobox gene. FEBS Letters 364,289-292.

Coucouvanis, E. and Martin, G. R. (1995). Signals for death and survival: a two-step mechanism for cavitation in the vertebrate embryo. Cell 83, 279-287.

Davis, C. A. and Joyner, A. L. (1988). Expression patterns of the homeobox-containing genes En-1 and En-2 and the proto-oncogene int-1 diverge during mouse development. Genes Dev. 2, 1736-1744

Doetschman, T. C., Eistetter, H., Katz, M., Schmidt, W. and Kemler, R. (1985). The in vitro development of blastocyst derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J. Embryol. Exp. Morph. 87, 27-45.

Echalard, Y. Epstein, D. J., St-Jacques, B., Shen, L., Mohler, J., McMahon, A. P. (1993). Sonic Hedgehog, a member of a family of putative signalling

58

hybridisation. *J. Neurosci. Res.* **25**, 194-203.

Li, M., Pevny, L., Lovell-Badge, R. and Smith, A. (1998). Generation of neural precursors from embryonic stem cells by lineage selection. *Current Biol.* **8**. 971-974.

5   Mahon, K. A., Westphal, H. and Gruss, P. (1988). Expression of the homeobox gene Hox 1.1 during mouse embryogenesis. *Development 104 Suppl*, 187-195.

Marti, E., Takada, R., Bumcrot, D. A., Sasaki, H. and McMahon, A. (1995). Distribution of Sonic hedgehog peptides in the developing chick and mouse
10   embryo. D*evelopment* **121**, 2537-2547.

Newgreen,   D.   F.   and   Minichiello,   J.   (1996).   Control   of Epitheliomesenchymal Transformation II. Cross-Modulation of Cell Adhesion and Cytoskeletal Systems in Embryonic Neural Cells. *Dev. Biol.* **176**, 300-312.

Nieto, M. A., Bradley, L. C. and Wilkinson, D. G. (1991). Conserved
15   segmental expression of Krox-20 in the vertebrate hindbrain and its relationship to lineage restriction. *Development Suppl.* **2**, 59-62.

Okabe S., Forsberg-Nilsson K., Spiro AC., Segal M., McKay RD. (1996). Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells *in vitro*. Mech Dev 59, 89-102.

20   Paxinos, G., Ashwell, K. W. S. and Törk, I. Atlas of the developing rat nervous system. 1994; Academic press, second edition, 24 Oval Road, London, UK.

Pevny, L. H., Sockanathan, S., Placzek, M. and Lovell-Badge, R. (1998). A role for SOX1 in neural determination. *Development* **125**, 1967-1978.

25   Price, M., Lazzaro, D., Pohl, T., Mattei, M. G., Ruther, U., Olivio, J. C.,

in vitro. Proc. Natl. Acad. Sci. U.S.A. **89**, 8240-8244.

Simeone, A. (1998). *Otx1* and *Otx2* in the development and evolution of the mammalian brain. *EMBO J.* **17**, 6790-6798.

Southarrd-Smith, E. M., Kos, L. and Pavan, W. J. (1998). Sox10 mutation
5   disrupts neural crest development in Dom Hirschsprung mouse model. *Nat. Genet* **18**, 60-64.

Studer, M., Gavalas, A., Marshall, H., Ariz-McNaughton, L., Rijli, F. M., Chambon, P. and Krumlauf, R. (1998). Genetic interactions between Hoxa1 and Hoxb1 reveal new roles in regulation of early hindbrain patterning. *Development*
10   **125**, 1025-1036.

Wassarman, K. M., Lewandoski, M., Campbell., K., Joyner, A. L., Rubenstein, J. L. R., Martinez, S. and Martin, G. R. (1997) Specification of the anterior hindbrain and establishment of a normal mid/hindbrain organizer is dependent on *Gbx2* function. *Development* **124**, 2923-2934.

15   Walther, C. and Gruss, P. (1991). Pax-6, a murine paired box gene, is expressed in the developing CNS. *Development* **113**,1435-1449.

Zimmerman, L., Parr, B., Lendahl, U., Cunningham, M., McKay, R., Gavin, B., Mann, J., Vassileva, G. and McMahon, A. (1994). Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or
20   muscle precursors. *Neuron* **12**, 11-24.

It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.

CLAIMS

1.   A method of producing neurectoderm cells, which method includes providing

a source of early primitive ectoderm-like (EPL) cells;

a conditioned medium as hereinbefore defined; or an extract therefrom exhibiting neural inducing properties; and

contacting the EPL cells with the conditioned medium or extract, for a time sufficient to generate controlled differentiation to neurectoderm cells.

2.   A method according to Claim 1 wherein the neurectoderm cells produced are early neurectoderm cells.

3.   A method according to Claim 1 wherein the neurectoderm cells exhibit neural plate-like characteristics.

4.   A method according to Claim 2, including further providing a suitable culture medium as hereinbefore defined, and

further culturing the early neurectoderm cells in the presence of the suitable culture medium while late neurectoderm cells are formed.

5.   A method according to Claim 4 wherein the late neurectoderm cells so produced exhibit neural tube-like characteristics.

6.   A method according to Claim 1, further including the preliminary steps of

providing

a source of pluripotent cells;

a source of a biologically active factor including

a low molecular weight component selected from the group consisting of proline and peptides including proline and functionally active fragments and analogues thereof; and

a large molecular weight component selected from the group consisting of extracellular matrix portions and functionally active

includes FGF4.

15.   A method according to Claim 14, wherein the FGF growth factor is present in the conditioned medium or extract in a concentration of approximately 1 to 100 ng/ml.

5   16.   A method according to Claim 4, wherein the EPL cells are cultured in the conditioned medium or extract for approximately 1 to 7 days.

17.   A method according to Claim 16 wherein the further culturing step is initiated on day 3.

18.   A method according to Claim 1, further including the step of
10   identifying the neurectoderm cells by procedures including gene expression markers, morphology and differentiation potential.

19.   A method according to Claim 18, wherein the conversion of EPL cells to neurectoderm cells is characterised by
down regulation of expression of *Oct4* relative to embryonic stem (ES) cells;
15   and; and one or more of
up regulation of expression of N-Cam and nestin;
up regulation of expression of *Sox1* and *Sox2*; and
initial up regulation of expression of *Gbx2*; followed by down regulation thereof as neurectoderm cells persist.

20   20.   A method according to Claim 19 wherein the upregulation of expression of *Gbx2* is indicative of neurectoderm cells having neural plate-like characteristics.

21.   A method according to Claim 19 wherein the upregulation of expression of *Gbx2* is indicative of neurectoderm cells having neural plate-like
25   characteristics and the subsequent downregulation of *Gbx2* is indicative of cells having neural tube-like characteristics.

neurectoderm cell culture step is conducted in the presence of a Protein Kinase Inhibitor.

30.   A method according to Claim 29, wherein the inhibitor is staurosporine.

5   31.   A method according to Claim 29, wherein the differentiated cells produced are substantially homogeneous populations of neural crest cells.

32.   A method according to Claim 28, wherein the additional neurectoderm cell culture step is conducted

in a first stage, in the presence of laminin, an FGF growth factor and an
10   EGF growth factor; and

in a second stage, in the presence of a PDGF growth factor and in the substantial absence of EGF, FGF and laminin.

33.   A method according to Claim 32, wherein the differentiated cells produced are substantially homogeneous populations of glial cells.

15   34.   A method according to Claim 28, wherein the additional neurectoderm cell culture step is conducted in the presence of the conditioned medium according to Claim 1.

35.   A method according to Claim 34, wherein the differentiated cells produced are neuronal cells in high frequency.

20   36.   A method for maintaining neurectoderm cells *in vitro* in cell populations that are substantially homogeneous, which method includes

providing

neurectoderm cells produced according to Claim 1; and

a suitable culture medium as hereinbefore defined;
25   further culturing the neurectoderm cells in the culture medium to form aggregates of neurectoderm cells.

Nkx2.2 and *Shh*.

44. A neurectoderm cell according to Claim 43, wherein the neurectoderm cell expresses neural identity genes selected from the group consisting of one or more of *Otx1, Mash1, En1, En2, Pax3* and *Pax6*.

5   45. A neurectoderm cell according to Claim 39, wherein the neurectoderm cell migrates and differentiates *in vivo* following brain implantation.

A neurectoderm cell according to Claim 45 wherein the neurectoderm cells disperse widely along the ventricle walls and into the sub-ependymal layer, and into deeper regions of the brain, including into the uninjected side of the brain into 10 sites that include the thalamus, frontal cortex, caudate putamen and colliculus, within the brain following intraventricular injection.

47. A neurectoderm cell according to Claim 46, wherein the neurectoderm cells differentiate to form neural lineages, including neurons and glia.

15   48. A neurectoderm cell, or partially or terminally differentiated neurectoderm cell, whenever produced by a method according to Claim 1.

49. A neurectoderm cell according to Claim 48, wherein the cell is the cell of a vertebrate selected from the group consisting of murine, human, bovine, ovine, porcine, caprine, equine and chicken.

20   50. A partially differentiated neuronal cell, or a terminally differentiated neuronal cell, a partially differentiated neural crest cell, or a terminally differentiated neural crest cell, a partially differentiated glial cell, or a terminally differentiated glial cell, whenever produced by a method according to any one of Claims 24 to 38 or derived from neurectoderm cells according to any of Claims 39 25 to 49.

conducted in the presence of a growth factor from the FGF family.

58.   A method of producing genetically modified neurectoderm cells, which method includes

providing

5   a source of genetically modified pluripotent cells;

a source of a biologically active factor including

a low molecular weight component selected from the group consisting of proline and peptides including proline and functionally active fragments and analogues thereof; and

10   a large molecular weight component selected from the group consisting of extracellular matrix portions and functionally active fragments or analogues thereof, or the low or large molecular weight component thereof;

a conditioned medium as hereinbefore defined; or an extract

15   therefrom exhibiting neural inducing properties;

contacting the pluripotent cells with the source of the biologically active factor, or the large or low molecular weight component thereof, to produce genetically modified early primitive ectoderm-like (EPL) cells; and

contacting the genetically modified EPL cells with the conditioned medium

20   or extract to produce genetically modified early neurectoderm cells.

59.   A method according to Claim 58, further including providing a suitable culture medium as hereinbefore defined, and

further culturing the early neurectoderm cells in the presence of the suitable culture medium for a time sufficient to form genetically modified late neurectoderm

25   cells.

60.   A method according to Claim 59, wherein the further culturing step is conducted in the presence of a growth factor from the FGF family.

61.   A genetically modified neurectoderm cell, a partially differentiated genetically modified neurectoderm cell, a terminally differentiated genetically

30   modified neuronal cell, a partially differentiated genetically modified neural crest

72

Parkinson's disease, Huntington's disease, lysosymal storage diseases, multiple sclerosis, memory and behavioural disorders, or Alzheimer's disease.

68.   A method for the preparation of tissue or organs for transplant, which method includes

5   providing neural crest cells or neurectoderm produced according to Claim 51 or 52; and

culturing the neural crest cells to produce neural or non-neural cells; and the neurectoderm cells to produce neural cells.

69.   A method according to Claim 1, substantially as hereinbefore

10   described with reference to any one of Examples 1 to 4.

70.   Use according to Claim 59, substantially as hereinbefore described with reference to Example 5.

FIGURES 1F, 1G, 1H, 1I, 1J, 1K

FIGURE 3

FIGURE 5

FIGURE 7

FIGURE 9

FIGURE 11

FIGURE 14

A.	CLASSIFICATION OF SUBJECT MATTER

Int. Cl. [7]:   C12N 5/06, 5/08

According to International Patent Classification (IPC) or to both national classification and IPC

B.	FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
WPIDS, CA: SEE ELECTRONIC DATA BASE BOX BELOW

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
MEDLINE: SEE ELECTRONIC DATA BASE BOX BELOW

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPIDS, MEDLINE: cell differentiation, neural crest, glial, ectoderm, neurectoderm, epl, primitive ectoderm, culture media, cell culture

C.	DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	**J Cell Science 113**, pages 555-66 (2000) Lake, J-A. et al "Reversible programming of pluripotent cell differentiation." See in particular pages 561-3, figure 6B	1-8, 12-68
X	**WO 9953021 A (BRESAGEN LIMITED) 21 October 1999** See pages 92, 93, 97-102, figure 34B	1-8, 12-68
X	**Development 126**, pages 3781-94 (1999) Hagedorn, L. et al "P0 and PMP22 mark a multipotent neural crest-derived cell type that displays community effects in response to TGF- family factors." See entire document	53, 54

[X] Further documents are listed in the continuation of Box C   [X] See patent family annex

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 February 2001	20 March 2001

Name and mailing address of the ISA/AU	Authorized officer
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	**TERRY MOORE** Telephone No : (02) 6283 2632

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member				
WO	99 53021	AU	33219/99	EP	1068295	
WO	99 32606	AU	25106/99	EP	1040185	
WO	94 02593	EP	658194	US	6033906	

END OF ANNEX